43 related articles for article (PubMed ID: 25433245)
1. Characterization of recombinant human lactoferrin N-glycans expressed in the milk of transgenic cows.
Parc AL; Karav S; Rouquié C; Maga EA; Bunyatratchata A; Barile D
PLoS One; 2017; 12(2):e0171477. PubMed ID: 28170415
[TBL] [Abstract][Full Text] [Related]
2. Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.
Pegg CL; Cooper LT; Zhao J; Gerometta M; Smith FM; Yeh M; Bartlett PF; Gorman JJ; Boyd AW
Sci Rep; 2017 Jul; 7(1):6519. PubMed ID: 28747680
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice.
Velusamy SK; Fine DH; Velliyagounder K
Microbes Infect; 2014 Sep; 16(9):762-7. PubMed ID: 25124544
[TBL] [Abstract][Full Text] [Related]
4. The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro.
Zimecki M; Artym J; Kocięba M; Duk M; Kruzel ML
Cell Mol Biol Lett; 2014 Jun; 19(2):284-96. PubMed ID: 24820230
[TBL] [Abstract][Full Text] [Related]
5. Thermal stability and in vitro biological fate of lactoferrin-polysaccharide complexes.
Jiang H; Zhang T; Pan Y; Yang H; Xu X; Han J; Liu W
Food Res Int; 2024 Apr; 182():114182. PubMed ID: 38519194
[TBL] [Abstract][Full Text] [Related]
6. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.
Hutt M; Färber-Schwarz A; Unverdorben F; Richter F; Kontermann RE
J Biol Chem; 2012 Feb; 287(7):4462-9. PubMed ID: 22147690
[TBL] [Abstract][Full Text] [Related]
7. A review of the safety evidence on recombinant human lactoferrin for use as a food ingredient.
Vishwanath-Deutsch R; Dallas DC; Besada-Lombana P; Katz L; Conze D; Kruger C; Clark AJ; Peterson R; Malinczak CA
Food Chem Toxicol; 2024 May; 189():114727. PubMed ID: 38735359
[TBL] [Abstract][Full Text] [Related]
8. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
9. Oral Delivery of Bovine Lactoferrin Using Pectin- and Chitosan-Modified Liposomes and Solid Lipid Particles: Improvement of Stability of Lactoferrin.
Yao X; Bunt C; Cornish J; Quek SY; Wen J
Chem Biol Drug Des; 2015 Oct; 86(4):466-75. PubMed ID: 25581616
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.
Jang YS; Seo GY; Lee JM; Seo HY; Han HJ; Kim SJ; Jin BR; Kim HJ; Park SR; Rhee KJ; Kim WS; Kim PH
Mucosal Immunol; 2015 Jul; 8(4):906-17. PubMed ID: 25492477
[TBL] [Abstract][Full Text] [Related]
11. Fc fusion as a platform technology: potential for modulating immunogenicity.
Levin D; Golding B; Strome SE; Sauna ZE
Trends Biotechnol; 2015 Jan; 33(1):27-34. PubMed ID: 25488117
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticular and other carriers to deliver lactoferrin for antimicrobial, antibiofilm and bone-regenerating effects: a review.
Ong R; Cornish J; Wen J
Biometals; 2023 Jun; 36(3):709-727. PubMed ID: 36512300
[TBL] [Abstract][Full Text] [Related]
13. A cytotoxic effect of human lactoferrin fusion with Fc domain of IgG.
Zaczyńska E; Kocięba M; Artym J; Kochanowska I; Kruzel ML; Zimecki M
Biometals; 2023 Jun; 36(3):617-627. PubMed ID: 36136256
[TBL] [Abstract][Full Text] [Related]
14. Sustained Delivery of Lactoferrin Using Poloxamer Gels for Local Bone Regeneration in a Rat Calvarial Defect Model.
Park YE; Chandramouli K; Watson M; Zhu M; Callon KE; Tuari D; Abdeltawab H; Svirskis D; Musson DS; Sharma M; Cornish J
Materials (Basel); 2021 Dec; 15(1):. PubMed ID: 35009359
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Direct and Cell-Mediated Lactoferrin Gene Therapy for the Maxillofacial Area Abscesses in Rats.
Agatieva E; Ksembaev S; Sokolov M; Markosyan V; Gazizov I; Tsyplakov D; Shmarov M; Tutykhina I; Naroditsky B; Logunov D; Pozdeev O; Morozova L; Yapparova K; Islamov R
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33406760
[TBL] [Abstract][Full Text] [Related]
16. The pain-relieving effects of lactoferrin on oxaliplatin-induced neuropathic pain.
Fujimura T; Iguchi A; Sato A; Kagaya S; Hoshino T; Takeuchi T
J Vet Med Sci; 2020 Dec; 82(11):1648-1654. PubMed ID: 32981900
[TBL] [Abstract][Full Text] [Related]
17. Optimized lactoferrin as a highly promising treatment for intracerebral hemorrhage: Pre-clinical experience.
Zhao X; Kruzel M; Ting SM; Sun G; Savitz SI; Aronowski J
J Cereb Blood Flow Metab; 2021 Jan; 41(1):53-66. PubMed ID: 32438861
[TBL] [Abstract][Full Text] [Related]
18. Potential Use of Biological Proteins for Liver Failure Therapy.
Taguchi K; Yamasaki K; Seo H; Otagiri M
Pharmaceutics; 2015 Aug; 7(3):255-74. PubMed ID: 26404356
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
